Schuit, Anouk S.
Holtmaat, Karen
Hooghiemstra, Nienke
Jansen, Femke
Lissenberg-Witte, Birgit I.
Coupé, Veerle M. H.
van Linde, Myra E.
Becker-Commissaris, Annemarie
Reijneveld, Jaap C.
Zijlstra, Josée M.
Sommeijer, Dirkje W.
Eerenstein, Simone E. J.
Verdonck-de Leeuw, Irma M.
Funding for this research was provided by:
ZonMw (844001105)
Article History
Received: 29 April 2019
Accepted: 20 September 2019
First Online: 23 October 2019
Ethics approval and consent to participate
: This study will be conducted in accordance with the Declaration of Helsinki and local laws and regulations. Patients who are eligible to participate in the study are fully informed about the study and are asked to participate. Interested patients receive a patient information form and are also informed about the study by phone or in a face-to-face conversation with the researcher. Patients have ample opportunity to ask questions before they decide to participate. Patients provide written informed consent before participation. Patients can withdraw from the study at any time without any consequences.The study protocol has been approved by the Medical Ethical Committee of VU University Medical Center, Amsterdam, The Netherlands (2018.224).
: Not applicable.
: IMVdL is named as the inventor of Oncokompas, the self-management application for patients with cancer that is used in this study. The other authors declare that they have no competing interests.